Deaths involving serotonergic drugs

Forensic Science International

Volumn 198, Issue 1-3, 2010, Pages 110-117

  Pilgrim, J L ^a   Gerostamoulos, D ^a   Drummer, Olaf H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Fatalities; MDMA; Serotonin toxicity; SSRI; Tramadol; Venlafaxine

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; AMPHETAMINE; ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; CODEINE; DEXTROPROPOXYPHENE; DIAZEPAM; DOSULEPIN; FLUOXETINE; FUROSEMIDE; GLICLAZIDE; IBUPROFEN; METHAMPHETAMINE; MIRTAZAPINE; MOCLOBEMIDE; NAPROXEN; NORDAZEPAM; OXAZEPAM; PARACETAMOL; PAROXETINE; PETHIDINE; QUETIAPINE; SEROTONIN; SERTRALINE; TRAMADOL; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ARTICLE; AUSTRALIA; CAUSE OF DEATH; DEATH; DRUG BLOOD LEVEL; DRUG MISUSE; FATALITY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 77952288961     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2010.01.014     Document Type: Article

References (75)

1. Sternbach H. The serotonin Syndrome. Am. J. Psychiatry 1991, 148:705-713.
2. Garay J., Plaza N., Castellano V., Tejada P. Serotonin syndrome: report of a fatal case and review of the literature. Rev. Clin. Esp. 2002, 202:209-211.
3. Ener R.A., Meglathery S.B., Van Decker W.A., Gallagher R.M. Serotonin syndrome and other serotonergic disorders. Pain Med. 2003, 4:63-74.
4. Keck P., Arnold L.M. The Serotonin syndrome. Psychiatr. Ann. 2000, 30:333-343.
5. Birmes P., Coppin D., Schmitt L., Lauque D. Serotonin syndrome: a brief review. CMA J. 2003, 168:1439-1442.
6. Bijl D. The Serotonin syndrome. Neth. J. Med. 2004, 62.
7. Dunkley E.J., Isbister G.K., Sibbritt D., Dawson A.H., Whyte I.M. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q. J. Med. 2003, 96:635-642.
8. Boyer E.W., Shannon M. The serotonin syndrome. N. Engl. J. Med. 2005, 352:1112-1120.
9. Gillman P.K. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br. J. Anaesth. 2005, 95:434-441.
10. Sporer K.A. The serotonin syndrome. Implicated drugs, pathophysiology and management. Drug Saf. 1995, 13:94-104.
11. Kitson R., Carr B. Tramadol and severe serotonin syndrome. Anaesthesia 2005, 60:934-935.
12. Kesavan S., Sobala G.M. Serotonin syndrome with fluoxetine plus tramadol. J. R. Soc. Med. 1999, 92:474-475.
13. Bush E., Miller C., Friedman I. A case of serotonin syndrome and mutism associated with methadone. J. Palliat. Med. 2006, 9:1257-1259.
14. Skop B.P., Finkelstein J.A., Mareth T.R., Magoon M.R., Brown T.M. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am. J. Emerg. Med. 1994, 12:642-644.
15. Kung S.W., Man Ho N.G. Serotonin syndrome with tramadol and dextromethorphan. Hong Kong J. Emerg. Med. 2007, 14:48-52.
16. Freezer A., Salem A., Irvine R.J. Effects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide. Brain Res. 2005, 1041:48-55.
17. Connolly E., O'Callaghan G. MDMA toxicity presenting with severe hyperpyrexia: a case report. Crit. Care Resusc. 1999, 1:368-370.
18. McCue R.E., Joseph M. Venlafaxine- and trazodone-induced serotonin syndrome. Am. J. Psychiatry 2001, 158:2088-2089.
19. Muly E.C., McDonald W., Steffens D., Book S. Serotonin syndrome produced by a combination of fluoxetine and lithium. Am. J. Psychiatry 1993, 150:1565.
20. Lane R., Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J. Clin. Psychopharmacol. 1997, 17:208-221.
21. Shi R., Winecker R.E., Lo S.F., Schneider R.J., Kin M., Schur B.C., Stremski E., Wong S.H. Pharmacogenomics for clinical and forensic toxicology - an adjunct for interpretation of drug toxicity. Pharmacogenomics and Proteomics: Enabling the Practice of Personalized Medicine 2006, AACC Press, Washington DC, USA.
22. Serretti A., Artioli P. The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J. 2004, 4:233-244.
23. Martin T.G. Serotonin syndrome. Ann. Emerg. Med. 1996, 28:520-526.
24. Bilbao Garay J., Mesa Plaza N., Castilla Castellano V., Dhimes Tejada P. Serotonin syndrome: report of a fatal case and review of the literature. Rev. Clin. Esp. 2002, 202:209-211.
25. Isbister G.K., McGettigan P., Dawson A. A fatal case of moclobemide-citalopram intoxication. J. Anal. Toxicol. 2001, 25:716-717.
26. Cassens S., Nickel E.A., Quintel M., Neumann P. The serotonin syndrome. Fatal course of intoxication with citalopram and moclobemide. Anaesthesist 2006, 55:1189-1196.
27. Clark D.B., Andrus M.R., Byrd D.C. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy 2006, 26:269-276.
28. Dams R., Benijts T.H., Lambert W.E., Van Bocxlaer J.F., Van Varenbergh D., Van Peteghem C., De Leenheer A.P. A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication. J. Anal. Toxicol. 2001, 25:147-151.
29. Drummer O.H. Postmortem toxicology of drugs of abuse. Forensic Sci. Int. 2004, 142:101-113.
30. The Forensic Pharmacology of Drugs of Abuse 2001, Arnold, Arnold. O.H. Drummer, M. Odell (Eds.).
31. Department of Health and Ageing (DHA), 2007.
32. G. Fowler, S. Kinner, L. Krenske, 2007. Containing ecstasy: analytical tools for profiling an illegal drug market (National Drug Law Enforcement Research Fund (NDLERF) ed, Tasmania.
33. Baetz M., Malcolm D. Serotonin syndrome from fluvoxamine and buspirone. Can. J. Psychiatry 1995, 40:428-429.
34. Dursun S.M., Mathew V.M., Reveley M.A. Toxic serotonin syndrome after fluoxetine plus carbamazepine. Lancet 1993, 342:442-443.
35. Houlihan D.J. Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Ann. Pharmacother. 2004, 38:411-413.
36. Karunatilake H., Buckley N.A. Serotonin syndrome induced by fluvoxamine and oxycodone. Ann. Pharmacother. 2006, 40:155-157.
37. Parrott A.C. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 2002, 71:837-844.
38. Reeves R.R., Bullen J.A. Serotonin syndrome produced by paroxetine and low-dose trazodone. Psychosomatics 1995, 36:159-160.
39. Canan F., Korkmaz U., Kocer E., Onder E., Yildirim S., Ataoglu A. Serotonin syndrome with paroxetine overdose: a case report. Prim. Care Companion J. Clin. Psychiatry 2008, 10:165-167.
40. Pan J.J., Shen W.W. Serotonin syndrome induced by low-dose venlafaxine. Ann. Pharmacother. 2003, 37:209-211.
41. Daniels R.J. Serotonin syndrome due to venlafaxine overdose. J. Accid. Emerg. Med. 1998, 15:333-334.
42. Mueller P.D., Korey W.S. Death by " ecstasy": the serotonin syndrome?. Ann. Emerg. Med. 1998, 32:377-380.
43. Gnanadesigan N., Espinoza R.T., Smith R., Israel M., Reuben D.B. Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?. J. Am. Med. Dir. Assoc. 2005, 6:265-269.
44. Gnanadesigan N., Espinoza R.T., Smith R.L. The serotonin syndrome. N. Engl. J. Med. 2005, 352:2454-2456. author reply 2454-2456.
45. Tjaderborn M., Jonsson A.K., Hagg S., Ahlner J. Fatal unintentional intoxications with tramadol during 1995-2005. Forensic Sci. Int. 2007.
46. KuKanich B., Papich M.G. Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. J. Vet. Pharmacol. Ther. 2004, 27:239-246.
47. Egberts A.C., ter Borgh J., Brodie-Meijer C.C. Serotonin syndrome attributed to tramadol addition to paroxetine therapy. Int. Clin. Psychopharmacol. 1997, 12:181-182.
48. Mason B.J., Blackburn K.H. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann. Pharmacother. 1997, 31:175-177.
49. Mahlberg R., Kunz D., Sasse J., Kirchheiner J. Serotonin syndrome with tramadol and citalopram. Am. J. Psychiatry 2004, 161:1129.
50. Eap C.B., Bertschy G., Powell K., Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J. Clin. Psychopharmacol. 1997, 17:113-117.
51. Begre S., von Bardeleben U., Ladewig D., Jaquet-Rochat S., Cosendai-Savary L., Golay K.P., Kosel M., Baumann P., Eap C.B. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J. Clin. Psychopharmacol. 2002, 22:211-215.
52. Weschules D.J., Bain K.T., Richeimer S. Actual and potential drug interactions associated with methadone. Pain Med. 2008, 9:315-344.
53. Kalant H. The pharmacology and toxicology of " ecstasy" (MDMA) and related drugs. CMA J. 2001, 165:917-928.
54. Vuori E., Henry J.A., Ojanpera I., Nieminen R., Savolainen T., Wahlsten P., Jantti M. Death following ingestion of MDMA (ecstasy) and moclobemide. Addiction 2003, 98:365-368.
55. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, " ecstasy" ). Pharmacol. Rev. 2003, 55:463-508.
56. Oesterheld J.R., Armstrong S.C., Cozza K.L. Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics 2004, 45:84-87.
57. Levisky J.A., Bowerman D.L., Jenkins W.W., Johnson D.G., Karch S.B. Drugs in postmortem adipose tissues: evidence of antemortem deposition. Forensic Sci. Int. 2001, 121:157-160.
58. Milroy C.M., Clark J.C., Forrest A.R. Pathology of deaths associated with " ecstasy" and " eve" misuse. J. Clin. Pathol. 1996, 49:149-153.
59. Pilgrim J.L., Gerostamoulos D., Drummer O.H., Bollmann M. Involvement of amphetamines in sudden and unexpected death. J. Forensic Sci. 2009, 54:478-485.
60. Lester S.J., Baggott M., Welm S., Schiller N.B., Jones R.T., Foster E., Mendelson J. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann. Intern. Med. 2000, 133:969-973.
61. Brown T.M., Skop B.P. Nitroglycerin in the treatment of the serotonin syndrome. Ann. Pharmacother. 1996, 30:191-192.
62. M. Rønning, 2009.
63. Whyte I.M., Dawson A.H., Buckley N.A. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Q. J. Med. 2003, 96:369-374.
64. Shipton E.A. Tramadol-present and future. Anaesth. Intensive Care 2000, 28:363-374.
65. Skopp G. Preanalytic aspects in postmortem toxicology. Forensic Sci. Int. 2004, 142:75-100.
66. A. Koski, University of Helsinki, Helsinki, Finland, 2005.
67. Madea B., Musshoff F. Postmortem toxicology. Forensic Sci. Int. 2004, 142:71-73.
68. M. Wagner, Columbia Pacific University Editor, 2003.
69. Munhoz R.P. Serotonin syndrome induced by a combination of bupropion and SSRIs. Clin. Neuropharmacol. 2004, 27:219-222.
70. Woodward M.C., Streeton C.L., Guttmann A., Killer G.T., Peck R.W. Polypharmacy management among Australian veterans: improving prescribing through the Australian Department of Veterans' Affairs' prescriber feedback programme. Intern. Med. J. 2008, 38:95-100.
71. Roughead E.E., McDermott B., Gilbert A.L. Antidepressants: prevalence of duplicate therapy and avoidable drug interactions in Australian veterans. Aust. N.Z. J. Psychiatry 2007, 41:366-370.
72. Roughead E.E., Anderson B., Gilbert A.L. Potentially inappropriate prescribing among Australian veterans and war widows/widowers. Intern. Med. J. 2007, 37:402-405.
73. Ringland C., Mant A., McGettigan P., Mitchell P., Kelman C., Buckley N., Pearson S.A. Uncovering the potential risk of serotonin toxicity in Australian veterans using pharmaceutical claims data. Br. J. Clin. Pharmacol. 2008, 66:682-688.
74. M. Welzen, D.A. Uges, 2004. TIAFT reference blood level list of therapeutic and toxic substances [document online]: (accessed 10 February 2010). http://www.tiaft.org/.
75. Norwegian Institute of Public Health, WHO Collaborating Centre for Drug Statistics Methodology, 1996.